Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Wearables are gaining traction in GI care, with devices showing promise for predicting IBD flares and tracking glucose in real time — but experts warn the tech isn't ready for routine clinical use. While many patients find the data motivating, others develop unnecessary anxiety from misread results. The verdict: useful, but proceed with caution and education.
Wearable devices are making inroads into gastroenterology, with over 40% of IBD patients already using or having used them. From HRV-tracking patches that can predict ulcerative colitis flares up to 7 weeks in advance, to sweat-based biosensors detecting inflammatory cytokines like TNF-alpha, the technology holds real promise for noninvasive, real-time disease monitoring. Continuous glucose monitors (CGMs) are also drawing attention for helping patients visualize how diet and activity affect their bodies — potentially nudging healthier choices.
But the picture isn't entirely straightforward. Experts caution that wearables aren't yet validated for routine clinical use, and the volume of data can backfire. Some patients misinterpret normal glucose spikes as red flags, while others develop anxiety-driven checking loops around sleep or activity data. The IDEA trial even found that wearable users lost less weight than those using standard behavioral interventions (3.5 vs 5.9 kg at 24 months).
Key Takeaways:
Why it matters: Wearables could transform GI care by enabling earlier intervention and personalized monitoring — but without proper patient education, clinical guardrails, and equitable access, their benefits may not outweigh the risks for all patients.
